Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis

(2014) D. Chen et al.   CLINICAL CANCER RESEARCH

The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance

(2014) Oscar Tapia et al.   VIRCHOWS ARCHIV

Systems Analysis of BCL2 Protein Family Interactions Establishes a Model to Predict Responses to Chemotherapy

(2013) A. U. Lindner et al.   CANCER RESEARCH

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

(2013) Roberta Schmieder et al.   INTERNATIONAL JOURNAL OF CANCER

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

(2013) Charles S Fuchs et al.   LANCET

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

(2013) Tom Waddell et al.   LANCET ONCOLOGY

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis

(2013) Andreas Krieg et al.   MOLECULAR BIOLOGY REPORTS

Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model

(2013) L. Abou-Elkacem et al.   MOLECULAR CANCER THERAPEUTICS

Signal Transduction by Vascular Endothelial Growth Factor Receptors

(2013) S. Koch et al.   Cold Spring Harbor Perspectives in Medicine

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

(2012) J H Yi et al.   BRITISH JOURNAL OF CANCER

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells

(2012) Lifeng Feng et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) George D Demetri et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Phosphorylation of histone H3 Ser10 establishes a hierarchy for subsequent intramolecular modification events

(2012) Stamatios Liokatis et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2011) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?

(2011) Tina Cascone et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinicopathological significance of platelet-derived growth factor (PDGF)-B and vascular endothelial growth factor-A expression, PDGF receptor-β phosphorylation, and microvessel density in gastric cancer

(2010) Shioto Suzuki et al.   BMC CANCER

Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk

(2010) L. E. Wroblewski et al.   CLINICAL MICROBIOLOGY REVIEWS

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

(2010) Yung-Jue Bang et al.   INVESTIGATIONAL NEW DRUGS

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Angiogenesis and Lymphangiogenesis of Gastric Cancer

(2010) Yasuhiko Kitadai   Journal of Oncology

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment

(2009) Britta Weigelt et al.   BREAST CANCER RESEARCH AND TREATMENT

AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer

(2009) S. Yang et al.   MOLECULAR CANCER THERAPEUTICS

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY